MedTrace Logo

Beta-thalassemia and Microparticles

NCT01284738 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2014-08-29

No results posted yet for this study

Summary

The results will allow us to evaluate the role of MP in the thrombo-embolic risk observed in thalassemic patients and to underline a possible difference between TM and TI. The in vitro and in vivo study of MP in erythrocytes concentrates is a new approach to explore the consequence of transfusion in polytransfused patients. Finally, the identification of a possible relationship between the oxidative stress and the production of MP may lead to the development of specific therapeutical approaches

Conditions

  • Thalassemia Major (TM)
  • Thalassemia Intermedia (TI)
  • Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes

Interventions

OTHER

Physiopathology

Three sequential biological evaluations will be performed for each patient and will consist in : * the dosages of MP carried out by the UMR 608 in Marseille, * the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat. In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units.

OTHER

Physiopathology

Three sequential biological evaluations will be performed for each patient and will consist in : * the dosages of MP carried out by the UMR 608 in Marseille, * the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Principal Investigators

  • Isabelle Thuret, Doctor · APHM

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284738 on ClinicalTrials.gov